A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE011 (ITA) · Dr. Jansen
consented 2022-05-01
Adverse events
Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-05-11 (study day 5); relationship: not assessed
Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-05-30 (study day 24); relationship: N
Grade 2 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2022-07-03 (study day 58); relationship: N
Grade 2 Constipation — outcome: RECOVERED/RESOLVED; onset 2022-12-27 (study day 235); relationship: not assessed
Grade 2 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2023-01-13 (study day 252); relationship: Y
Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-03-11 (study day 309); relationship: not assessed
Grade 2 Fatigue — outcome: RECOVERED/RESOLVED; onset 2023-04-12 (study day 341); relationship: Y
Grade 3 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-05-07 (study day 366); relationship: N
Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-10-24 (study day 536); relationship: N
Data queries
No data queries.